Please assess the completion status of the following clinical trial:

Trial Title: Diabetes Mellitus Type II and Tissue Oxygenation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~We will include 30 patients who have more than a five-year history of insulin-dependent type-2 diabetes mellitus and 30 non-diabetic patients meeting the following criteria:~* 35 - 65 yrs old~* BMI \< 30~* ASA class I - III~* Abdominal surgery scheduled to last between 2- 4 hours~For Non-diabetic group:~previous BMP within the last year demonstrating glucose \< 126mg/dL~For Diabetic group:~* DMII defined as fasting plasma glucose of \> 126 mg/dL at time of diagnosis, now requiring insulin~* At least one diabetes associated vasculopathy: coronary artery disease, diabetic nephropathy, hypertension, diabetic retinopathy, diffuse neuropathy, peripheral vascular disease, or a history of stroke~Exclusion Criteria:~* Pregnant~* Immunocompromised: HIV/AIDS, on immunosuppressant therapy for any reason, or post-organ transplantation.~* Infection or fever, or on glucocorticoids~* Malignancy currently requiring radiation or chemotherapy~* Liver or renal failure~* Pancreatic insufficiency, dysautonomia, thyroid disease, Raynaud's syndrome, pathologic Allen-test, or any coagulopathies~* Respiratory disease affecting ability to reach PaO2 of 300mmHg: COPD, emphysema, cystic fibrosis, asthma, pneumonia, PE~* Smoker within the past 6 months or current alcohol abuse~* Allergy to local anesthetic~* For diabetics: DMI, other specific subtype, and gestational diabetics~* We will also exclude patients with epidural catheter, to avoid the influence of regional anesthesia on tissue oxygenation \[37, 38\].

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): None
- 2 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).